… We aimed to investigate whether adjuvant erlotinib therapy improves 2-year disease-free
survival compared with chemotherapy in epidermal growth factor receptor (EGFR) mutation-…

… To note, we observed that erlotinib treatment inhibited the phosphorylation of ERK and AKT
in … may have additional alterations that could determine the sensitivity to erlotinib inhibition. …

… C]erlotinib between erlotinib-sensitive and erlotinib-resistant NSCLC cells. Our findings suggest
that [ 11 C]erlotinib PET will not be suitable to distinguish erlotinib-… resistance to erlotinib. …

… with molecular docking methods elucidate binding characteristics and the domain in
which the dye resides in a micro heterogeneous environment is established in this study. …

… considered in the present study. As the erlotinib PAP was no longer available based on the
manufacturer's latest policy, the economic analysis did not consider this scenario for erlotinib. …

… In this report, we show that erlotinib enhances STAT3 phosphorylation by downregulation
of … of SCCHN to erlotinib treatment. Niclosamide, as a STAT3 inhibitor, can block erlotinib-…

… This study describes clinical outcomes among lung cancer patients initiating crizotinib or
erlotinib in routine clinical practice. Differences between SOI rates in EU and US may be …

… Lind JS, Lagerwaard FJ, Smit EF, Senan S (2009) Phase I study of concurrent whole brain
radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J …

… In this study, we introduced an erlotinib derivative, TD52, with potential antitumour effects in
TNBC. We found that CIP2A was a major determinant in TD52-mediated apoptosis. Through …

8059 Background: The non-comparative BRAIN study (NCT00800202) is the first trial to
evaluate efficacy/acceptable safety of B in pts with ns-NSCLC and untreated BM. We report final …